Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran ; volume:22 ; number:1 ; day:13 ; month:11 ; year:2024 ; pages:1-10 ; date:12.2024
Cost effectiveness and resource allocation ; 22, Heft 1 (13.11.2024), 1-10, 12.2024
- Urheber
-
Metghalchi, Yalda
Yaghoubi, Neda
Yousefi, Nazila
Ahmadi, Razieh
Kargar, Alireza
Zargaran, Marzieh
Rezaei, Soheila
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12962-024-00592-7
- URN
-
urn:nbn:de:101:1-2502040922425.737320639760
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Metghalchi, Yalda
- Yaghoubi, Neda
- Yousefi, Nazila
- Ahmadi, Razieh
- Kargar, Alireza
- Zargaran, Marzieh
- Rezaei, Soheila
- SpringerLink (Online service)
Ähnliche Objekte (12)
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
Tocilizumab: A Review in Rheumatoid Arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
Nine Rheumatoid Factor Assays Compared
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
Tocilizumab: A Review in Rheumatoid Arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
Nine Rheumatoid Factor Assays Compared
Clinical efficacy of abatacept compared to adalimumab and tocilizumab in rheumatoid arthritis patients with high disease activity
Cost-effectiveness of adalimumab for rheumatoid arthritis in Germany
Reply to: Need for improvements in reported cost-effectiveness of adalimumab in rheumatoid arthritis
Tocilizumab: A Review in Rheumatoid Arthritis
Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: a single-center study
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Adalimumab regulates intracellular TNFα production in patients with rheumatoid arthritis
Benefit–Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis